Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: Hank who wrote (3419)	4/17/1998 12:33:00 PM
From: Dauntless	Respond to of 7041

Hank, it's amazing how picky you can be My comment was one of several points intended to discredit Jay comparison of the Zonagen/Oppenheimer situation from that of Pharmaprint and whomever. Technically, SGP is not yet liable for those milestone payments. However, assuming that the Vasomax story plays out as I expect it to, those payments WILL come due. I know, you don't think it will happen that way, so try this... Take out the $47 million from my argument & it still makes the point. Zonagen, unlike Pharmaprint, is not desperate for cash & is unlikely to be raising any soon - so Jay's associated implication that Oppenheimer issued the rec in order to profit by participating in a fundraising was bogus - like I said, a cheap shot. You're reaching pretty damn deep to find something to rail against.